Ablexis is a leading brand that offers a superior, next generation transgenic mouse platform for the discovery of therapeutic antibodies. Founded in 2009, Ablexis has combined decades of experience and deep expertise to create a better platform for antibody drug discovery. They have developed the AlivaMab Mouse, a transgenic mouse that significantly improves upon other antibody discovery platforms.

This groundbreaking technology has been licensed by a majority of the world's top-15 pharmaceutical companies and is being used at over a dozen sites worldwide for antibody drug discovery. Ablexis understands the critical role that the choice of platform plays in every step of the discovery and development processes. By incorporating insights from molecular genetics, immunoglobulin loci function, human and mouse genome sequencing, and their experience in antibody drug discovery, they have created a platform that generates therapeutic antibody candidates with high potency, specificity, solubility, and reduced chance of immunogenicity.

In addition to their licensing partnerships, Ablexis has also established AlivaMab Discovery Services, a separate company that leverages the AlivaMab Mouse for discovery projects conducted on behalf of clients. Through this collaboration, Ablexis offers their clients access to a scientifically-driven organization with a deep understanding of therapeutic antibody discovery and development. Ablexis is committed to revolutionizing antibody drug discovery and is the go-to brand for those seeking innovative solutions in this field.

Ablexis is based in San Diego, California and can be contacted at 415. 967. 1220.

For more information, please visit their website at www. alivamab. com